Qiagen N.V. — Diagnostics & Research. Scored on the same transparent model behind the daily rankings.
★
QGEN
Qiagen N.V. · Diagnostics & Research
FCF$453mC
Rev+5.7%C+
D/E0.49B
P/E22.2xB+
PEG1.10B+
68.3Score
$43.74$9.0B
1Y Target$46.07Analyst consensus · 14 analysts
5Y Target$67.45Compound horizon
10Y Target$100.06Long-dated conviction
FCF$453mTTMC
FCF $453m — modest; watch for margin expansion
Rev+5.7%TTM YoYC+
Revenue +5.7% — steady but below market-beating range
D/E0.49B
D/E 0.49 — near the Healthcare debt median (≈60th pctile)
P/E22.2xB+
P/E 22.2 — below the Healthcare median (≈40th pctile)
PEG1.10B+
PEG 1.10 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 68.3
Quality64.7
Growth63.1
Value78.0
Why this score
Buying back stock
Entry · Margin of safety
52-week rangeMid-range
24% off the 12-month high
vs DCF fair value14% belowest. fair value ~$51
What the price assumes: free cash flow compounding at ~2% a year for the next decade — vs the ~7% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability21% · Bgross profit ÷ total assets (Novy-Marx)
ROIC6.8% · C+return on invested capital — not score-weighted
Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.
Why now
Qiagen’s market‑leading nucleic‑acid purification kits, especially its silica‑membrane and magnetic‑bead consumables used in clinical diagnostics and TB interferon‑gamma release assays, are set to capture expanding molecular‑testing volumes. The business is already delivering 5.7% revenue growth YoY, a healthy 20.3% profit margin, and generates $453 m of free cash flow (TTM), while the Bull Rankings model awards a Quality‑Growth score of 68.3 – with Value as its strongest pillar and Growth the weakest. Because the reverse‑DCF implies only ~2% FCF growth for the next decade, well below the 5.7% top‑line growth we see, the stock is priced for modest optimism, leaving clear upside if the growth trajectory holds.
Moat
Qiagen’s moat rests on its proprietary silica‑membrane and magnetic‑bead technologies that underpin its nucleic‑acid purification kits, creating high switching costs for labs that have built workflows around these consumables. The company’s entrenched relationships with clinical and research customers, combined with a 11.2% ROE driven by pricing power in the sample‑to‑insight market, make it difficult for generic competitors to erode its market share quickly.
Risk
The biggest headwind is the modest growth premium baked into the current valuation: a PE of 22.2 is high for a 5.7% revenue growth rate, and the Bull Rankings model flags Growth as the weakest pillar, suggesting the compounding engine may stall. If margin pressure intensifies or competitors launch cheaper kit alternatives, the stock could slump toward its 52‑week low of $32.53, confirming the bear case.
Horizon
1-3 yr $46.07 (14-analyst consensus) — fundamentals + valuation re-rating. 5 yr $67.45 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $100.06 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
QGEN vs the Top Picks average
Pillar
QGEN
Book avg
Diff
Quality
0.65
0.83
-0.19
Growth
0.63
0.87
-0.24
Value
0.78
0.76
in line
Averaged across the 30 names in today's Top Picks (mean score 81.6). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · QGEN
Trend
-0.1 over 51 daily scores
From 68.4 (Jun 22) → 68.3 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
QGEN at a glance
Every figure here comes from the same audited fundamentals behind the score. Charts drawn from data the score does not use say so on the card.
Analyst estimate revisions
30-day change
-0.5%
90-day change
-1.0%
Forward EPS estimate
$2.61
Over the last 90 days, what analysts expect QGEN to earn is essentially unchanged. The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Position sizing · QGEN
$
%
%
Shares to buy
45
Position size
$1,968
3.9% of portfolio
Stop price
$32.80
25% below $43.74
$ at risk if stopped
$492.08
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Qiagen N.V. (QGEN): score, valuation & FAQ
Qiagen N.V. (QGEN) is a Diagnostics & Research company that scores 68.3 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (B+) and PEG (B+). On valuation, QGEN sits about 14% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 2% annual free-cash-flow growth over the next decade.
Is QGEN a good stock to buy?
Bull Rankings scores QGEN 68.3 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (B+) and PEG (B+). A score is a quantitative screen of Qiagen N.V.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does QGEN score 68.3 on Bull Rankings?
The score leans on value at 78.0 out of 100, with growth the weakest pillar at 63.1 — the three combine geometrically, so a weak one cannot be papered over by a strong one. QGEN earns its highest marks on P/E (B+) and PEG (B+). Each signal is graded against sector-aware thresholds rather than one absolute bar, so QGEN is measured against Diagnostics & Research peers, not against the market as a whole.
Is QGEN overvalued or undervalued?
Based on $43.74, QGEN sits about 14% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 2% annual free-cash-flow growth over the next decade. It trades at a 22.2x P/E (graded B+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in QGEN?
The biggest headwind is the modest growth premium baked into the current valuation: a PE of 22.2 is high for a 5.7% revenue growth rate, and the Bull Rankings model flags Growth as the weakest pillar, suggesting the compounding engine may stall. If margin pressure intensifies or competitors launch cheaper kit alternatives, the stock could slump toward its 52‑week low of $32.53, confirming the bear case.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.
More Medical Devices & Diagnostics stocks by score